Cargando…
Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388526/ https://www.ncbi.nlm.nih.gov/pubmed/37525264 http://dx.doi.org/10.1186/s13063-023-07546-z |
| _version_ | 1785082138428702720 |
|---|---|
| author | Bai, Wei Yang, Fan Xu, Huji Wei, Wei Li, Hongbin Zhang, Liyun Zhao, Yi Shi, Xiaofei Zhang, Yan Zeng, Xiaofeng Leng, Xiaomei |
| author_facet | Bai, Wei Yang, Fan Xu, Huji Wei, Wei Li, Hongbin Zhang, Liyun Zhao, Yi Shi, Xiaofei Zhang, Yan Zeng, Xiaofeng Leng, Xiaomei |
| author_sort | Bai, Wei |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10388526 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103885262023-08-01 Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients Bai, Wei Yang, Fan Xu, Huji Wei, Wei Li, Hongbin Zhang, Liyun Zhao, Yi Shi, Xiaofei Zhang, Yan Zeng, Xiaofeng Leng, Xiaomei Trials Correction BioMed Central 2023-07-31 /pmc/articles/PMC10388526/ /pubmed/37525264 http://dx.doi.org/10.1186/s13063-023-07546-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Bai, Wei Yang, Fan Xu, Huji Wei, Wei Li, Hongbin Zhang, Liyun Zhao, Yi Shi, Xiaofei Zhang, Yan Zeng, Xiaofeng Leng, Xiaomei Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients |
| title | Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients |
| title_full | Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients |
| title_fullStr | Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients |
| title_full_unstemmed | Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients |
| title_short | Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients |
| title_sort | correction: a multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary sjogren’s syndrome patients |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388526/ https://www.ncbi.nlm.nih.gov/pubmed/37525264 http://dx.doi.org/10.1186/s13063-023-07546-z |
| work_keys_str_mv | AT baiwei correctionamulticenteropenlabelrandomizedstudytoexploreefficacyandsafetyofbaricitinibinactiveprimarysjogrenssyndromepatients AT yangfan correctionamulticenteropenlabelrandomizedstudytoexploreefficacyandsafetyofbaricitinibinactiveprimarysjogrenssyndromepatients AT xuhuji correctionamulticenteropenlabelrandomizedstudytoexploreefficacyandsafetyofbaricitinibinactiveprimarysjogrenssyndromepatients AT weiwei correctionamulticenteropenlabelrandomizedstudytoexploreefficacyandsafetyofbaricitinibinactiveprimarysjogrenssyndromepatients AT lihongbin correctionamulticenteropenlabelrandomizedstudytoexploreefficacyandsafetyofbaricitinibinactiveprimarysjogrenssyndromepatients AT zhangliyun correctionamulticenteropenlabelrandomizedstudytoexploreefficacyandsafetyofbaricitinibinactiveprimarysjogrenssyndromepatients AT zhaoyi correctionamulticenteropenlabelrandomizedstudytoexploreefficacyandsafetyofbaricitinibinactiveprimarysjogrenssyndromepatients AT shixiaofei correctionamulticenteropenlabelrandomizedstudytoexploreefficacyandsafetyofbaricitinibinactiveprimarysjogrenssyndromepatients AT zhangyan correctionamulticenteropenlabelrandomizedstudytoexploreefficacyandsafetyofbaricitinibinactiveprimarysjogrenssyndromepatients AT zengxiaofeng correctionamulticenteropenlabelrandomizedstudytoexploreefficacyandsafetyofbaricitinibinactiveprimarysjogrenssyndromepatients AT lengxiaomei correctionamulticenteropenlabelrandomizedstudytoexploreefficacyandsafetyofbaricitinibinactiveprimarysjogrenssyndromepatients |